drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive TIL infusion)
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) therapy expanded ex vivo; adoptive cellular immunotherapy delivering tumor-reactive T cells to mediate antigen-specific cytotoxicity and effector cytokine secretion.
nci_thesaurus_concept_id
C200139
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs GT201 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating lymphocytes are isolated from the patient’s tumor, expanded ex vivo, and reinfused. These non-engineered T cells use their native TCRs to recognize tumor antigens presented by MHC on cancer cells, execute antigen-specific cytotoxicity (perforin/granzyme) and secrete effector cytokines (e.g., IFN-γ, TNF-α), enhancing antitumor immune responses.
drug_name
GT201
nct_id_drug_ref
NCT06190275